2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original Research
2017
Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries
Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, Wilson IB. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS 2017, 31: 1697-1707. PMID: 28700393, PMCID: PMC5625296, DOI: 10.1097/qad.0000000000001541.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersII receptor blockersHIV patientsControl medicationTherapy persistenceReceptor blockersEnzyme inhibitors/angiotensin II receptor blockersCox proportional hazards modelNon-HIV medicationsUS Medicaid beneficiariesHIV-negative controlsRetrospective cohort studyKaplan-Meier curvesDuration of treatmentProportional hazards modelTen-year trendsSecular trendsART initiatorsCohort studyHazard ratioMedian timeFill dateMedicaid claimsMedicaid beneficiariesAdjusted model
2016
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess risk